Medacta Group Sa · SIX:MOVE
Medacta Group Sa — H1 2020 Earnings Presentation
13 slides from Medacta Group Sa's earnings presentation, Jul 22, 2020
Slide 1: 1H 2020 Sales: Unaudited top-line figures
1H 2020 Sales Unaudited top-line figures 22nd July 2020 PATIENT WELL-BEING MEDICAL EDUCATION INNOVATION 1
Slide 2: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by Medacta Group SA ("Medacta" and together with its subsidiaries, "we", "us" or the "Group"). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on ou
Slide 3: Today's presenters
Today’s presenters Francesco Siccardi Corrado Farsetta Chief Executive Officer Chief Financial Officer Joined Medacta in 2002; Member of the Board since 2003 2002 to 2010 in charge of marketing, product and business development, with a particular focus on the US market Served as Executive VP of Meda
Slide 4: Agenda
Agenda 1H 2020 Unaudited Revenue 4
Slide 5: Medacta Revenue and COVID19 impact (unaudited figures)
Medacta Revenue and COVID19 impact (unaudited figures) 1H 2020 was heavily affected by COVID-19 impact, with: • Revenue at €134.8 million, • Growth -11.1% vs prior year (-12.2% in CC1 ) Orthopedic surgeries have been deferred. Patients requiring Orthopedic Procedures are generating Waiting Lists, wh
Slide 6: 1H 2020: Revenue bridge by Region (unaudited figures)
1H 2020: Revenue bridge by Region (unaudited figures) Revenue Bridge by Region FY 2019 A Growth 7.9% 13.2% 13.3% 28.1% 11.3%1 (€M) % 2019 ACT Constant 1H 2019 A Growth 8.2% 17.7% 7.6% 18.2% 11.0%1 Currency Growth y-o-y 1H 2020 A Growth -17.3% -14.3% 5.8% -28.4% -12.21 -11.1% % 2020 ACT Constant 151.
Slide 7: 1H 2020: Revenue bridge by Product (unaudited figures)
1H 2020: Revenue bridge by Product (unaudited figures) Revenue Bridge by Product FY 2019 A Growth 5.2% 13.2% 147.4% 23.4% 11.3%1 (€M) % 2019 ACT Constant 1H 2019 A Growth 6.4% 13.5% 171.3% 11.0% 11.0%1 Currency Growth y-o-y 1H 2020 A Growth -17.5% -13.0% 41.7% 11.9% -12.2%1 -11.1% % 2020 ACT Constan
Slide 8: Redesigned Marketing and Education Implementation
Redesigned Marketing and Education Implementation Thanks to several new marketing initiatives and education programs we were able to keep existing surgeons involved and engage new customers, leveraging national experts. #1’800+ surgeons attended our on-line education programs, with significant savin
Slide 9: Product Innovation
Product Innovation 25+ New Products cleared (CE or FDA) in 1H in line with MDR/MDD switch original plan including: Hip: • Renewed Primary Implants offering (Quadra-P Family) • Expansion of Revision Implants offering (M-Vizion Femoral Revision Range Extention) • Introduction of Personalised 3D Hip Pl
Slide 10: Product Innovation
Product Innovation • Medacta developed the first FDA-Cleared Augmented Reality-Based Surgical Platform for Total Knee Replacement • Low upfront capital investment • Reduced cost per case vs other technologies • Advanced personalised planning tools • Unique soft tissue assessment • Accurate Surgical
Slide 11: Outlook 2020
Outlook 2020 Sales in 1H were heavily affected by the Covid-19, generating for the first time in the company’s history a negative growth. Lockdowns at the end of Q2 were lifted in almost all the countries but the negative evolution of COVID-19 in several countries could seriously affect the speed of
Slide 12: Outlook 2020
Outlook 2020 The sales performances in the final part of first semester returned to be positive, confirming that backlog recovery can occur quickly if the environmental conditions allow. Even if the June sales performance are encouraging, speed and size of recovery in 2H depend on the evolution of t
Slide 13: THANK YOU
Adedacta International THANK YOU 13